Serial monitoring of BCR–ABL by peripheral blood real‐time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia
Open Access
- 15 August 2002
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 118 (3), 771-777
- https://doi.org/10.1046/j.1365-2141.2002.03705.x
Abstract
Summary. Imatinib mesylate (trade name Glivec® or Gleevec) is emerging as an important therapy in the management of chronic myeloid leukaemia (CML). It is clinically useful to monitor the cytogenetic response to imatinib, although frequent marrow examinations are inconvenient. We have used serial real‐time reverse transcription–polymerase chain reaction (RT‐PCR) to monitor the ratio of peripheral blood BCR–ABL to normal ABL transcripts in 43 patients receiving imatinib, and compared the results to concurrent conventional bone marrow (BM) cytogenetics. After 6 months of treatment, 13 cases were complete cytogenetic responders, defined as all BM metaphases negative for the Philadelphia (Ph) chromosome. In these patients, the BCR–ABL/ABL ratio was less than 0·08%. Six cases achieved a partial cytogenetic response (1–35% Ph‐positive BM metaphases) and their BCR–ABL/ABL ratio was between 0·08 and 10%. In total, 24 cases were cytogenetic non‐responders, and their BCR–ABL/ABL ratio exceeded 11%. The data suggested that the 6‐month BCR–ABL/ABL ratio may reliably predict the contemporary marrow cytogenetic response. It was concluded that serial real‐time RT‐PCR may offer a convenient surrogate assessment of the marrow cytogenetic response to imatinib therapy in CML.Keywords
This publication has 31 references indexed in Scilit:
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogeneticsBritish Journal of Haematology, 1999
- Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCRLeukemia, 1999
- Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assayLeukemia, 1999
- Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real‐time quantitative RT‐PCRBritish Journal of Haematology, 1998
- APPROPRIATE CONTROLS FOR REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT‐PCR)British Journal of Haematology, 1994
- Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1994
- Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemiaThe Lancet, 1993
- Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaAin Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1986